IP Library › Granted Patent US 9,850,308
Granted Patent B2
US 9,850,308 · App. 14/700,521 · Granted Dec 26, 2017

Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

Inventors: Ana Martin-Villalba (Heidelberg, DE); Susanne Kleber (Heidelberg, DE); Benedikt Wiestler (Schriesheim, DE); Peter G. Krammer (Heidelberg, DE); Christel Herold-Mende (Bammental, DE); Ignacio Sancho-Martinez (Heidelberg, DE)
Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS; UNIVERSITAETSKLINIKUM HEIDELBERG
C07K16/2875A61K38/00C07K14/70575C07K14/70578G01N33/566G01N33/57407G01N33/6863A61K2039/505C07K16/2878C07K2317/76C07K2319/00C07K2319/30G01N2333/70578G01N2500/00G01N2500/04G01N2500/10G01N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,850,308
App. No.
14/700,521
Granted
Dec 26, 2017
Kind
B2
Abstract

The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Claims (7)

1. A method for treating high grade glioma in an individual, comprising administering to an individual having high grade glioma the only active ingredient of an anti-human CD95 ligand (CD95L) antibody or an antigen binding fragment thereof that neutralizes CD95L activity, wherein the only active ingredient is administered in an amount sufficient to reduce glial cell migration and/or invasion.

2. The method of claim 1 , wherein the only active ingredient is an antibody that binds to human CD95L.

3. The method of claim 2 , wherein the antibody is Nok1.

4. The method of claim 1 , wherein the high grade glioma is a WHO Grade III or IV glioma.

5. The method of claim 1 , wherein the high grade glioma is a WHO Grade IV glioma.

6. The method of claim 1 , wherein the only active ingredient is administered in the amount to reduce the glial cell migration to invade the contralateral hemisphere.

7. The method of claim 1 , wherein the high grade glioma is glioblastoma multiforme.

Continuity (3)
Continuation 12521625
Provisional Application 60877367 · Dec 28, 2006
Related Publication 20160115236A1 · Apr 28, 2016